American Thoracic Society - Sanofi Investor Call
sanofi
Significant reduction in FeNO observed with SAR'765 suggests
the potential for a highly competitive target product profile
Mean (±SEM) change from baseline over time
30
Placebo
(n=12)
SAR443765 (400mg) 18,8
(n=24)
-0,8
10
0
Nitric oside (ppb)
-10
-30
-50
Baseline
Results of SAR'765 on FeNO suggest a synergistic
effect compared to TSLP or IL13 alone¹-8
0
0,8
-10
Phase 1b¹ PATHWAY² NAVIGATOR³ SOURCE4
MILLY5
LUTE &
VERSE6
STRATOS7 MESOS8
-20
-31,9
-35,2
-30
-39,1
-40
Anti-TSLP trials
Day 8
Anti-IL-13 trials
Day 15
Day 29
-50
Highly elevated FeNO at baseline, consistent with active,
Type 2 airway inflammation
SAR443765
-40.9 ppb
Confirmed pharmacodynamic effect, with FeNO as clinically
relevant biomarker for type 2 airway inflammation
(90% CI: -55.4 to -26.4)*
FeNO, fractional exhaled nitric oxide. The clinical significance of FeNO is under investigation *Not head-to-head comparisons; patient populations and baseline characteristics may differ between studies. Estimates of FeNO change from baseline versus
plaecbo derived from published data. +Difference vs placebo estimate from a mixed-effects model over time taking into account baseline FeNO and sex as co-variates. 1. Gavreau GM, et al NEJM. 2014;370:2102-10; 2. Corren JC, et al. NEJM. 2017;377:936;
3. Menzies-Gow A, et al. NEJM. 2021;384:1800-09; 4. Weschler M, et al. Lancet Respir Med. 2022;10:650-60; 5. Corren JC, et al. NEJM. 2011;365:1088-98; 6. Hanania NA, et al. Thorax. 2015;70:748-56; 7. Panettieri RA, et al. Lancet Respir Med.
2018;6:511-25; 8. Russell RJ, et al. Lancet Respir Med. 2018;6:499-510.
41 ATS Investor CallView entire presentation